- Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. Wassmann, B., Pfeifer, H., Scheuring, U.J., Binckebanck, A., Gökbuget, N., Atta, J., Brück, P., Rieder, H., Schoch, C., Leimer, L., Schwerdtfeger, R., Ehninger, G., Lipp, T., Perz, J., Stelljes, M., Gschaidmeier, H., Hoelzer, D., Ottmann, O.G. Blood (2004)